Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI106580

The effects of the morphine analogue levorphanol on leukocytes: Metabolic effects at rest and during phagocytosis

Nancy Wurster, Peter Elsbach, Eric J. Simon, Penelope Pettis, and Sharon Lebow

1Department of Medicine, New York University School of Medicine, New York 10016

Find articles by Wurster, N. in: JCI | PubMed | Google Scholar

1Department of Medicine, New York University School of Medicine, New York 10016

Find articles by Elsbach, P. in: JCI | PubMed | Google Scholar

1Department of Medicine, New York University School of Medicine, New York 10016

Find articles by Simon, E. in: JCI | PubMed | Google Scholar

1Department of Medicine, New York University School of Medicine, New York 10016

Find articles by Pettis, P. in: JCI | PubMed | Google Scholar

1Department of Medicine, New York University School of Medicine, New York 10016

Find articles by Lebow, S. in: JCI | PubMed | Google Scholar

Published May 1, 1971 - More info

Published in Volume 50, Issue 5 on May 1, 1971
J Clin Invest. 1971;50(5):1091–1099. https://doi.org/10.1172/JCI106580.
© 1971 The American Society for Clinical Investigation
Published May 1, 1971 - Version history
View PDF
Abstract

Studies on bacteria have suggested that morphine-like drugs have effects on the cell membrane. To determine the effect of this class of drugs on a mammalian cell, we selected the rabbit peritoneal exudate granulocyte, which undergoes striking membrane changes during phagocytosis. We examined the effect in vitro of the morphine analogue, levorphanol on phagocytosis and metabolism by granulocytes incubated with and without polystyrene particles or live Escherichia coli. Levorphanol (1 or 2 mmoles/liter) decreased: (a) acylation of lysolecithin or lysophosphatidylethanolamine in the medium (which is stimulated about two-fold during phagocytosis) both at rest (40%) and during phagocytosis (60%); (b) uptake of latex particles and Escherichia coli, as judged by electron microscopy; (c) killing of live Escherichia coli (10-fold); (d) 14CO2 production from glucose-1-14C during phagocytosis by at least 80%; (e) K+ content of granulocytes (35%); (f) oxidation of linoleate-1-14C by 50%, and its incorporation into triglyceride by more than 80%. However, levorphanol stimulated 2 to 3-fold the incorporation of linoleate-1-14C or palmitate-1-14C into several phospholipids. Glucose uptake, lactate production, and adenosine triphosphate (ATP) content are not affected by the drug. Thus, levorphanol does not appear to exert its effects through generalized metabolic suppression.

Removal of levorphanol by twice resuspending the granulocytes completely reverses all inhibition.

In line with observations on bacteria, it appears that the complex effects of levorphanol on granulocytes may be due at least in part to an effect on the cell membrane.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1091
page 1091
icon of scanned page 1092
page 1092
icon of scanned page 1093
page 1093
icon of scanned page 1094
page 1094
icon of scanned page 1095
page 1095
icon of scanned page 1096
page 1096
icon of scanned page 1097
page 1097
icon of scanned page 1098
page 1098
icon of scanned page 1099
page 1099
Version history
  • Version 1 (May 1, 1971): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts